Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Evofem Biosciences Inc is a biotechnology business based in the US. Evofem Biosciences shares (EVFM) are listed on the NASDAQ and all prices are listed in US Dollars. Evofem Biosciences employs 147 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.70|
|52-week range||$0.65 - $5.53|
|50-day moving average||$0.77|
|200-day moving average||$1.00|
|Wall St. target price||$3.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-0.52%|
|1 month (2021-09-24)||-9.64%|
|3 months (2021-07-26)||-18.14%|
|6 months (2021-04-26)||-54.39%|
|1 year (2020-10-26)||-71.79%|
|2 years (2019-10-25)||-85.95%|
|3 years (2018-10-26)||3.35|
|5 years (2016-10-26)||1.26|
|Revenue TTM||$3.4 million|
|Gross profit TTM||$78,000|
|Return on assets TTM||-75.84%|
|Return on equity TTM||-387.27%|
|Market capitalisation||$108.3 million|
TTM: trailing 12 months
There are currently 27.7 million Evofem Biosciences shares held short by investors – that's known as Evofem Biosciences's "short interest". This figure is 2.3% down from 28.4 million last month.
There are a few different ways that this level of interest in shorting Evofem Biosciences shares can be evaluated.
Evofem Biosciences's "short interest ratio" (SIR) is the quantity of Evofem Biosciences shares currently shorted divided by the average quantity of Evofem Biosciences shares traded daily (recently around 3.3 million). Evofem Biosciences's SIR currently stands at 8.51. In other words for every 100,000 Evofem Biosciences shares traded daily on the market, roughly 8510 shares are currently held short.
However Evofem Biosciences's short interest can also be evaluated against the total number of Evofem Biosciences shares, or, against the total number of tradable Evofem Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evofem Biosciences's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Evofem Biosciences shares in existence, roughly 180 shares are currently held short) or 0.198% of the tradable shares (for every 100,000 tradable Evofem Biosciences shares, roughly 198 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Evofem Biosciences.
Find out more about how you can short Evofem Biosciences stock.
We're not expecting Evofem Biosciences to pay a dividend over the next 12 months.
Evofem Biosciences's shares were split on a 1:6 basis on 17 January 2018. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evofem Biosciences shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Evofem Biosciences shares which in turn could have impacted Evofem Biosciences's share price.
Over the last 12 months, Evofem Biosciences's shares have ranged in value from as little as $0.654 up to $5.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evofem Biosciences's is -0.3856. This would suggest that Evofem Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Evofem Biosciences has bucked the trend.
Evofem Biosciences, Inc. , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.